title: Paclitaxel, carboplatin and gemcitabine combination as induction chemotherapy for stage IIIA N2 bulky non-small cell lung cancer.
abstract: BACKGROUND
  Induction chemotherapy followed by surgical resection or definitive radiotherapy for patients affected by stage IIIA N2 bulky non-small cell lung cancer (NSCLC) has been investigated in several trials.
  
  
  METHODS
  In this present study, 52 patients with stage IIIA N2 bulky NSCLC with cytologically or histologically confirmed mediastinal lymph node involvement received paclitaxel 175 mg/mq on day 1, carboplatin AUC 5 on day 1 and gemcitabine 1,000 mg/mq on day 1 and 8 every 3 weeks for three cycles as induction chemotherapy.
  
  
  RESULTS
  Objective response (4 complete remission and 36 partial remission) was achieved in 40/52 patients. No early or toxic deaths were observed. Twenty-two patients were surgically explored. Fifteen were excluded for resection for biopsy-proven residual tumour in mediastinal nodes. Complete surgical resection was performed in 15 patients with confirmed pathological downstaging. Pathological complete response was achieved in 4 patients. No surgery-related mortality or significant morbidity was reported. Adjuvant radiotherapy was delivered in 15 patients, and 30 patients received definitive radiotherapy.
  
  
  CONCLUSIONS
  In the present study, the combination of paclitaxel, carboplatin and gemcitabine has been a safe and active regimen in poor-prognosis stage IIIA N2 bulky NSCLC.
authors.affiliation: Oncology Unit, Gravina Hospital, Caltagirone, and Department of Oncology, Università di Palermo, Italy.
authors.forename: Giorgio Carmelo
authors.initials: GC
authors.lastname: Giannitto
authors.forename: Dario
authors.initials: D
authors.lastname: Giuffrida
authors.forename: Alessandro
authors.initials: A
authors.lastname: Pappalardo
authors.forename: Antonio
authors.initials: A
authors.lastname: Russo
authors.forename: Bruno
authors.initials: B
authors.lastname: Vincenzi
authors.forename: Salvino
authors.initials: S
authors.lastname: Saita
authors.forename: Enrico
authors.initials: E
authors.lastname: Potenza
authors.forename: Franco
authors.initials: F
authors.lastname: Marletta
authors.forename: Giuseppe
authors.initials: G
authors.lastname: La Venia
authors.forename: Sergio
authors.initials: S
authors.lastname: Castorina
authors.forename: Roberto
authors.initials: R
authors.lastname: Bordonaro
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D012074:Remission Induction; D016019:Survival Analysis; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D016190:Carboplatin; D017239:Paclitaxel; D000093542:Gemcitabine